Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

1741. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. Full Text available with Trip Pro

Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. Type 1 diabetes mellitus (DM) results from a cell-mediated autoimmune attack against pancreatic beta cells. Previous animal and clinical studies suggest that moderate immunosuppression in newly diagnosed type 1 DM can prevent further loss of insulin production and can reduce insulin needs.To determine the safety and metabolic effects of high-dose immunosuppression followed (...) by autologous nonmyeloablative hematopoietic stem cell transplantation (AHST) in newly diagnosed type 1 DM.A prospective phase 1/2 study of 15 patients with type 1 DM (aged 14-31 years) diagnosed within the previous 6 weeks by clinical findings and hyperglycemia and confirmed with positive antibodies against glutamic acid decarboxylase. Enrollment was November 2003-July 2006 with observation until February 2007 at the Bone Marrow Transplantation Unit of the School of Medicine of Ribeirão Preto, Ribeirão

2007 JAMA

1742. Exercise reduces resistin and inflammatory cytokines in patients with type 2 diabetes. Full Text available with Trip Pro

Exercise reduces resistin and inflammatory cytokines in patients with type 2 diabetes. Exercise reduces resistin and inflammatory cytokines in patients with type 2 diabetes. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 (...) selected item: 17327348 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2007 Mar;30(3):719-21. Exercise reduces resistin and inflammatory cytokines in patients with type 2 diabetes. 1 , , , , , . 1 First Propedeutic Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

2007 EvidenceUpdates

1743. Pioglitazone did not reduce macrovascular complications and increased HF in type 2 diabetes with macrovascular disease

Pioglitazone did not reduce macrovascular complications and increased HF in type 2 diabetes with macrovascular disease Pioglitazone did not reduce macrovascular complications and increased HF in type 2 diabetes with macrovascular disease | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Pioglitazone did not reduce macrovascular complications and increased HF in type 2 diabetes with macrovascular disease Article Text Therapeutics

2007 Evidence-Based Medicine

1744. Inhaled insulin added to or replacing 2 oral agents reduced haemoglobin A1c concentrations in type 2 diabetes Full Text available with Trip Pro

Inhaled insulin added to or replacing 2 oral agents reduced haemoglobin A1c concentrations in type 2 diabetes Inhaled insulin added to or replacing 2 oral agents reduced haemoglobin A1c concentrations in type 2 diabetes | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Inhaled insulin added to or replacing 2 oral agents reduced haemoglobin A1c concentrations in type 2 diabetes Article Text Treatment Inhaled insulin added to or replacing 2 oral

2007 Evidence-Based Nursing

1745. Zinc supplementation for the prevention of type 2 diabetes mellitus. Full Text available with Trip Pro

Zinc supplementation for the prevention of type 2 diabetes mellitus. The chronic hyperglycaemia of diabetes is associated with long-term damage, dysfunction, and failure of various organs, especially the eyes, kidneys, nerves, heart, and blood vessels. The risk of developing type 2 diabetes increases with age, obesity, and lack of physical activity. Insulin resistance is a fundamental aspect of the aetiology of type 2 diabetes. Insulin resistance has been shown to be associated (...) with atherosclerosis, hypertriglyceridaemia, glucose intolerance, dyslipidaemia, hyperuricaemia, hypertension and polycystic ovary syndrome. The mineral zinc plays a key role in the synthesis and action of insulin, both physiologically and in diabetes mellitus. Zinc seems to stimulate insulin action and insulin receptor tyrosine kinase activity.To assess the effects of the zinc supplementation in the prevention of type 2 diabetes mellitus.Studies were obtained from computerised searches of MEDLINE, EMBASE, LILACS

2007 Cochrane

1746. In the clinic. Type 2 diabetes. (Abstract)

In the clinic. Type 2 diabetes. It is nearly impossible to be a practicing internist in the United States and have a day of clinical work pass without encountering at least 1 patient with type 2 diabetes. Currently, over 20 million Americans and over 150 million worldwide have type 2 diabetes. Models estimate that this number will nearly double by the year 2050 so that about one third of adult Americans will have the disease. This In the Clinic feature includes answers to these and other (...) practical, clinical questions... What are the diagnostic criteria for type 2 diabetes in nonpregnant adults? Should we screen for type 2 diabetes? Can we prevent type 2 diabetes? What should the initial evaluation of patients with newly diagnosed type 2 diabetes include? What measures do U.S. stakeholders use to evaluate the quality of care for patients with type 2 diabetes? Only ACP members and individual subscribers can access the electronic features of In the Clinic. Non-subscribers who wish

2007 Annals of Internal Medicine

1747. Rapid-acting insulin analogues in the treatment of diabetes mellitus type 1

in Health Care Dillenburger Str. 27 51105 Cologne Germany Tel: +49-(0)221/35685-0 Fax: +49-(0)221/35685-1 E-mail: berichte@iqwig.de Website: www.iqwig.de Institute for Quality and Efficiency in Health Care (IQWiG) - 2 - Executive summary of final report A05-02 Version 1.0 30.03.2007 Rapid-acting insulin analogues in the treatment of diabetes mellitus type 1 Executive summary Background The German Federal Joint Committee commissioned the Institute for Quality and Efficiency in Health Care to conduct (...) Rapid-acting insulin analogues in the treatment of diabetes mellitus type 1 Executive Summary IQWiG Reports - Commission No. A05-02 Rapid-acting insulin analogues in the treatment of diabetes mellitus type 1 1 1 Translation of the executive summary of the final report “Kurzwirksame Insulinanaloga zur Behandlung des Diabetes mellitus Typ 1” (Version 1.0; Status: 30.03.2007). Publication date of translation: 25.06.2007. Please note: This translation is provided as a service by IQWiG to English

2007 Institute for Quality and Efficiency in Healthcare (IQWiG)

1748. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. Full Text available with Trip Pro

Interleukin-1-receptor antagonist in type 2 diabetes mellitus. The expression of interleukin-1-receptor antagonist is reduced in pancreatic islets of patients with type 2 diabetes mellitus, and high glucose concentrations induce the production of interleukin-1beta in human pancreatic beta cells, leading to impaired insulin secretion, decreased cell proliferation, and apoptosis.In this double-blind, parallel-group trial involving 70 patients with type 2 diabetes, we randomly assigned 34 patients

2007 NEJM Controlled trial quality: predicted high

1749. Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial. Full Text available with Trip Pro

Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial. To quantify the psychological impact of primary care based stepwise screening for type 2 diabetes.Controlled trial and comparative study embedded in a randomised controlled trial.15 practices (10 screening, five control) in the ADDITION (Cambridge) trial in the east of England.7380 adults (aged 40-69) in the top fourth for risk of having (...) undiagnosed type 2 diabetes (6416 invited for screening, 964 controls).Invited for screening for type 2 diabetes or not invited (controls), incorporating a comparative study of subgroups of screening attenders. Attenders completed questionnaires after a random blood glucose test and at 3-6 months and 12-15 months later. Controls were sent questionnaires at corresponding time points. Non-attenders were sent questionnaires at 3-6 months and 12-15 months.State anxiety (Spielberger state anxiety inventory

2007 BMJ Controlled trial quality: predicted high

1750. Patients' experiences of screening for type 2 diabetes: prospective qualitative study embedded in the ADDITION (Cambridge) randomised controlled trial. Full Text available with Trip Pro

Patients' experiences of screening for type 2 diabetes: prospective qualitative study embedded in the ADDITION (Cambridge) randomised controlled trial. To provide insight into factors that contribute to the anxiety reported in a quantitative study of the psychological effect of screening for type 2 diabetes. To explore expectations of and reactions to the screening experience of patients with positive, negative, and intermediate results.Prospective qualitative interview study of patients (...) test, type 2 diabetes was considered a strong possibility, albeit a "mild" form. After diagnosis, people with screen detected type 2 diabetes tended to downplay its importance and talked confidently about their plans to control it. Participants with intermediate results seemed uncertain about their diagnosis, and those who screened negative were largely unaware of their remaining high risk.This study helps in understanding the limited psychological impact of screening for type 2 diabetes quantified

2007 BMJ Controlled trial quality: uncertain

1751. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. (Abstract)

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Blood pressure is an important determinant of the risks of macrovascular and microvascular complications of type 2 diabetes, and guidelines recommend intensive lowering of blood pressure for diabetic patients with hypertension. We assessed the effects of the routine administration of an angiotensin (...) converting enzyme (ACE) inhibitor-diuretic combination on serious vascular events in patients with diabetes, irrespective of initial blood pressure levels or the use of other blood pressure lowering drugs.The trial was done by 215 collaborating centres in 20 countries. After a 6-week active run-in period, 11 140 patients with type 2 diabetes were randomised to treatment with a fixed combination of perindopril and indapamide or matching placebo, in addition to current therapy. The primary endpoints were

2007 Lancet Controlled trial quality: predicted high

1752. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. Full Text available with Trip Pro

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. Adding insulin to oral therapy in type 2 diabetes mellitus is customary when glycemic control is suboptimal, though evidence supporting specific insulin regimens is limited.In an open-label, controlled, multicenter trial, we randomly assigned 708 patients with a suboptimal glycated hemoglobin level (7.0 to 10.0%) who were receiving maximally tolerated doses of metformin and sulfonylurea to receive biphasic

2007 NEJM Controlled trial quality: uncertain

1753. Insulin treatment in type 2 diabetes

Insulin treatment in type 2 diabetes Volumen 15. DTB Navarre. Vol 15, No 5. November - December 2007 - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DTB Navarre. Vol 15, No 5. November - December 2007 DTB Navarre. Vol 15, No 5. November - December 2007 Content tools Share it Insulin treatment in type 2 diabetes Type 2 diabetes is a major health problem due to its high prevalence, its long-term complications and the implication

2007 Drug and Therapeutics Bulletin of Navarre (Spain)

1754. Self-Monitoring of Blood Glucose in Patients with Type 2 Diabetes Mellitus: Meta Analysis of Effectiveness

Self-Monitoring of Blood Glucose in Patients with Type 2 Diabetes Mellitus: Meta Analysis of Effectiveness Evidence-based Synthesis Program Self-Monitoring of Blood Glucose in Patients with Type 2 Diabetes Mellitus: Meta Analysis of Effectiveness Department of Veterans Affairs Health Services Research & Development Service September 2007 Investigators: Paul Shekelle, MD, PhD Director Brett Munjas, BA Project Manager/Literature Database Manager Maria Romanova, MD Ali Towfigh, MD Physician (...) Synthesis Program – iii Home Glucose Monitoring EXECUTIVE SUMMARY BACKGROUND Diabetes is a prevalent and costly disease in Veterans. Control of blood glucose is an important VA objective. Self-monitoring of blood glucose (SMBG) is advocated as a method to better achieve control. The Key Questions were: Key Question 1. Is regular SMBG effective in achieving target A1c levels for patients with type 2 diabetes? Key Question 2. Is regular SMBG effective in maintaining target A1c levels for patients

2007 Veterans Affairs Evidence-based Synthesis Program Reports

1755. Self-monitoring of blood glucose in type-2 diabetes: what is the evidence?

Self-monitoring of blood glucose in type-2 diabetes: what is the evidence? Self-monitoring of blood glucose in type-2 diabetes: what is the evidence? Self-monitoring of blood glucose in type-2 diabetes: what is the evidence? McGeoch G, Derry S, Moore RA CRD summary This review assessed the evidence for self-monitoring of blood glucose in type 2 diabetes and concluded that it could be beneficial in some circumstances (for example, as an educational tool). Although the findings reflected (...) the presented evidence, the poor study quality and uncertainty over parts of the review process suggest that the authors’ conclusions should be treated with caution. Authors' objectives To assess the evidence for self-monitoring of blood glucose in type 2 diabetes. Searching EMBASE, MEDLINE and The Cochrane library were searched from 1990 to November 2006. Further searches were made using Google and Google Scholar. Reference lists of included studies and reviews were searched to identify additional articles

2007 DARE.

1756. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials

Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

1757. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison

Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison Ilag L L, Kerr L, Malone J K, Tan M H CRD summary (...) This review investigated the efficacy and safety of prandial premixed insulin analogue regimens compared with basal insulin analogue regimens in the management of type 2 diabetes. The authors concluded that the results indicated better glycaemic control with premixed insulin regimens than with basal insulin regimens. In view of the methodological limitations of the review, this conclusion should be interpreted with caution. Authors' objectives To investigate the efficacy and safety of prandial premixed

2007 DARE.

1758. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

1759. The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker

The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

1760. Systematic literature review: quality of life associated with insulin pump use in type 1 diabetes Full Text available with Trip Pro

Systematic literature review: quality of life associated with insulin pump use in type 1 diabetes Systematic literature review: quality of life associated with insulin pump use in type 1 diabetes Systematic literature review: quality of life associated with insulin pump use in type 1 diabetes Barnard K D, Lloyd C E, Skinner T C CRD summary This review concluded that evidence of quality-of-life benefits with continuous subcutaneous insulin infusion in patients with type 1 diabetes is conflicting (...) . The authors attributed this largely to the methodological limitations of the included studies. The authors did not carry out a formal assessment of study quality so this assertion remains speculative. Authors' objectives To review the published literature on the impact of continuous subcutaneous insulin infusion(CSII) on the quality of life of people with type 1 diabetes. Searching Published studies were sought in MEDLINE, PsycINFO, CINAHL and EMBASE up to July 2005. In addition, the Diabetes UK website

2007 DARE.